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Abstract
Segment 7 of influenza A virus produces up to four mRNAs. Unspliced transcripts encode M1, spliced mRNA2 encodes the
M2 ion channel, while protein products from spliced mRNAs 3 and 4 have not previously been identified. The M2 protein
plays important roles in virus entry and assembly, and is a target for antiviral drugs and vaccination. Surprisingly, M2 is not
essential for virus replication in a laboratory setting, although its loss attenuates the virus. To better understand how IAV
might replicate without M2, we studied the reversion mechanism of an M2-null virus. Serial passage of a virus lacking the
mRNA2 splice donor site identified a single nucleotide pseudoreverting mutation, which restored growth in cell culture and
virulence in mice by upregulating mRNA4 synthesis rather than by reinstating mRNA2 production. We show that mRNA4
encodes a novel M2-related protein (designated M42) with an antigenically distinct ectodomain that can functionally
replace M2 despite showing clear differences in intracellular localisation, being largely retained in the Golgi compartment.
We also show that the expression of two distinct ion channel proteins is not unique to laboratory-adapted viruses but, most
notably, was also a feature of the 1983 North American outbreak of H5N2 highly pathogenic avian influenza virus. In
identifying a 14th influenza A polypeptide, our data reinforce the unexpectedly high coding capacity of the viral genome
and have implications for virus evolution, as well as for understanding the role of M2 in the virus life cycle.
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Introduction
Influenza A virus (IAV) is a genetically diverse pathogen of
global significance, responsible for seasonal epidemics and
sporadic pandemics in humans, as well as outbreaks in domestic
animals. Its primary reservoir is wild birds, but it can infect a wide
range of vertebrate species. For these reasons, there is the need to
develop better therapeutics and vaccines [1]. Current vaccines
target the surface glycoproteins haemagglutinin (HA) and neur-
aminidase (NA), but these proteins are subject to antigenic change,
necessitating regular updating of the vaccine to ensure a good
antigenic match to the circulating strains. Next generation
influenza vaccines seek to induce broader or ‘universal’ protection
against conserved epitopes; for example, the ‘stalk’ region of HA
or the ectodomain of the matrix 2 ion channel protein (M2) [2,3].
The IAV genome consists of eight segments of negative sense,
single stranded RNA (vRNA), each encapsidated into ribonucleo-
proteins (RNPs) by the viral RNA dependent RNA polymerase
and multiple copies of the viral nucleoprotein (NP). Upon
infection, incoming RNPs are imported into the nucleus, where
the vRNA is transcribed to give positive sense mRNA, and also
cRNA, which acts as a replication intermediate. The approxi-
mately 13 kb genome has so far been demonstrated to encode up
to 13 proteins [4,5]. Segments 1, 4, 5 and 6 each encode a single
protein: PB2, HA, NP and NA respectively. However, segments 2,
3, 7 and 8 have additional protein coding capacity. Segments 2
and 3, whose primary protein products are the polymerase
proteins PB1 and PA respectively, additionally produce PB1-F2,
PB1-N40 and PA-X proteins from single mRNA species by leaky
ribosomal scanning and translation termination-reinitiation in the
case of segment 2 and +1 ribosomal frameshifting for segment 3
[4–7].
In segments 7 and 8, protein coding capacity is expanded by
differential mRNA splicing. For segment 8, a single spliced species
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has been described, producing NS2/NEP, while NS1 is produced
from the unspliced transcript [8,9]. Segment 7 mRNA splicing is
more complex, as three spliced transcripts have been described
(designated mRNAs 2–4) in addition to the unspliced mRNA1
[10–12]. Unspliced mRNA1 gives rise to M1 protein. The spliced
mRNAs use a common 39-splice acceptor (SA) site, but use
different 59-splice donor (SD) sites (Fig. 1A). To date, only
mRNA2 has been demonstrated to encode a protein: the M2 ion
channel [13]. mRNA3 is produced from the most 59-proximal SD,
and is proposed to negatively regulate segment 7 protein
expression during early infection [14], a non-essential function
for virus growth in tissue culture [15,16]. More recently, mRNA4
has been shown to be produced by the A/WSN/33 (WSN) strain
of virus [12,15,17]. It hypothetically encodes an internally deleted
form of the M1 protein (‘‘M4’’; Fig. 1A) but this protein has not
been detected [12].
M2 is a 97 aa integral membrane protein, functional as a
homotetramer, with multiple important roles during the virus
lifecycle [18,19]. Each monomer consists of a 24 aa N-terminal
ectodomain, a transmembrane a-helix and a ,50 aa cytoplasmic
domain that contains a membrane proximal amphipathic alpha
helix [20,21]. M2 has proton channel activity, which is important
for acidification of the interior of the virion upon entry [22–24]. In
some strains of virus, proton conductance plays an additional role
in modulating the pH of the Golgi compartment to prevent
premature activation of the HA fusion apparatus [22,25]. The
cytoplasmic tail of M2 also has roles in virus assembly, budding
and morphogenesis [26–32]. The function of the ectodomain is
less well described, although along with the transmembrane
domain, it likely plays a role in directing the membrane topology
of M2 [33,34]. It may also be important for incorporation of the
protein into virions [35]. Nevertheless, the ectodomain is highly
conserved amongst virus strains and this has made it an attractive
candidate for a universal influenza vaccine [2,3].
Surprisingly, it has been possible to generate M2 null viruses,
either by introduction of stop codons or by mutating the splice
donor site, although these viruses are highly attenuated [15,36–
39]. Here, we describe a pseudoreversion mechanism of a virus
with a mutated mRNA2 SD site, which reveals a new aspect of
IAV biology. After serial passage, we identified a single mutation
that upregulated mRNA4 expression without restoring M2
synthesis. Instead, mRNA4 encodes an M2 variant with an
alternative ectodomain, designated here M42, which nevertheless
functionally complements M2, in vitro and in vivo. Furthermore, we
present evidence that certain strains of IAV, most notably those
responsible for the 1983 Pennsylvania outbreak of highly
pathogenic avian influenza (HPAI), normally express M42. Our
data extend the known IAV proteome and have implications for
virus evolution and vaccine design.
Results
Pseudoreversion of an M2-null virus
Previously, we used reverse genetics to create an A/PR/8/34
(PR8) virus with synonymous mutations to the mRNA 2 SD
sequence. This virus, (M1 V7-T9, hereafter named V7-T9), did
not produce detectable levels of M2 and was highly attenuated in
tissue culture [37]. To better understand the role of M2 in the
virus life cycle, we studied the mechanism by which V7-T9 could
regain fitness upon serial passage.
WT and V7-T9 viruses were subjected to six rounds of serial
passage via low multiplicity infections of MDCK cells. At each
round, outputs were titred by plaque and HA assay. Before serial
passage (‘‘P0’’), the input V7-T9 virus replicated to a plaque titre
400-fold lower than the WT and had an HA titre 100-fold lower
(Fig. 2A). However, on serial passage it regained fitness rapidly,
producing similar plaque and HA titres to WT virus within two
passages. As a further test of fitness recovery, the plaque areas of
the WT and V7-T9 viruses were measured before and after serial
passage. Prior to serial passage, V7-T9 displayed a small plaque
phenotype ([37]; Fig. 2B). However, after passage six (P6), its
average plaque area had increased over four-fold and was no
longer significantly different from that of the WT virus (Fig. 2B).
To test if the regained fitness resulted from restoration of M2
expression, we examined infected cell lysates from the original and
serially passaged versions of the WT and V7-T9 viruses by western
blotting for M1 and M2. All infected cells showed abundant M1
expression, confirming infection (Figs. 2C). Cells infected with the
WT virus isolates also contained a polypeptide recognised by the
M2 ectodomain-specific 14C2 monoclonal antibody, but as before
[37], cells infected with the original V7-T9 virus did not; a
phenotype that remained unchanged in the serially passaged
isolate (Fig. 2C, lanes 2–5). However, 14C2 antibody recognition
is restricted to an epitope encompassing residues 4 to 16 of M2
[40–42]. When a polyclonal antibody raised against the entire M2
protein, G74 [43], was used, the original V7-T9 virus still did not
show any reactivity (Fig. 2C). However, the P6 V7-T9 virus
produced detectable amounts of a G74-reactive polypeptide of
similar electrophoretic mobility to that of M2 (Fig. 2C, compare
lanes 4 and 5), suggesting that it now expressed some M2
polypeptide, albeit with different antigenicity to the WT protein.
To further investigate M2 expression by the P6 V7-T9 virus, we
examined cells infected with passaged or unpassaged WT and
mutant viruses by indirect immunofluorescence for NP (to identify
infected cells) and M2, using the two M2-specific sera. All infected
cells stained strongly for NP, confirming similar levels of infection
(Fig. 3; in red). Consistent with the western blot data, WT virus
infected cells also stained strongly with both 14C2 and G74 anti-
M2 antibodies, showing the expected predominant staining of
apical and lateral membranes [44], while neither isolate of the V7-
T9 virus reacted with the 14C2 monoclonal (Fig. 3; in green or
Author Summary
Influenza A virus is a pathogen capable of infecting a wide
range of avian and mammalian hosts, causing seasonal
epidemics and pandemics in humans. In recent years, the
unexpected coding capacity of the virus has begun to be
unravelled, with the identification of three more protein
products (PB1-F2, PB1-N40 and PA-X) on top of the 10 viral
proteins originally identified 30 years ago. Here, we
identify a 14th primary translation product, made from
segment 7. Previously established protein products from
segment 7 include the matrix (M1) and ion channel (M2)
proteins. M2, made from a spliced transcript, has multiple
roles in the virus lifecycle including in entry and budding.
In a laboratory setting, it is possible to generate M2
deficient viruses, but these are highly attenuated. Howev-
er, upon serial passage a virus lacking the M2 splice donor
site quickly recovered wild type growth properties,
without reverting the original mutation. Instead we found
a compensatory single nucleotide mutation had upregu-
lated another segment 7 mRNA. This mRNA encoded a
novel M2-like protein with a variant extracellular domain,
which we called M42. M42 compensated for loss of M2 in
tissue culture cells and animals, although it displayed some
differences in subcellular localisation. Our study therefore
identifies a further novel influenza protein and gives
insights into the evolution of the virus.
A Novel Form of the Influenza A Virus M2 Protein
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separate channel in grey). Also consistent with the western blot
data, the unpassaged V7-T9 virus did not stain above background
levels with the G74 antiserum, but the P6 isolate showed clear
reactivity. However, the staining pattern was markedly different to
that shown by WT virus, with prominent perinuclear staining and
some staining of lateral membranes (Fig. 3B). Overall, these data
suggested that the serially passaged M2 null virus had regained
fitness by expressing a variant form of M2 that no longer reacted
with the ectodomain-specific antibody.
Following serial passage, segment 7 of both the P6 WT and V7-
T9 viruses was sequenced. No changes were detected in the WT
virus compared to the reference sequence (GenBank accession
Figure 1. Segment 7 transcript and ORF structure. (A). Diagrammatic summary of mRNA splice variants. The nucleotide coordinates of SD and
SA sites are shown. Potential ORFs are colour coded (yellow, M1; blue, M2; red, unique sequence of M42) and total sizes (codons/aa) are given on the
right. The arrowhead at top right indicates the binding site of the oligonucleotide used to detect the various mRNA species by radioactive primer
extension reactions. (B) Nucleotide sequence (shown as cDNA) and predicted ORFs (colour coded as in (A)) of the 59-end of PR8 mRNA4. Unused SD
sequences and the splice junction (SJ) sequence are underlined. Nucleotides mutated to remove the M42 AUG codon (U115C) or abolish mRNA4
synthesis (G145A) are shown in red. (C) Alignment of the predicted N-terminal sequences of M2 and M42. The range of residues implicated in
recognition of M2 by the 14C2 antibody are indicated in red [40–42,61]. The transmembrane domain of M2 is shaded in green.
doi:10.1371/journal.ppat.1002998.g001
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EF467824). The P6 V7-T9 virus retained the original mutations
that destroyed the mRNA2 SD site, indicating pseudoreversion to
recover WT growth properties rather than true reversion. It also
contained a single additional change, not seen in the original V7-
T9 virus, of a U to A substitution at nucleotide 148 (U148A;
mRNA sense, Fig. S1). This change is in the M2 intron and is
silent in M1. However, the change would be predicted to improve
the mRNA4 SD consensus (Fig. S1), from AG/GUU to AG/GUA
[45]. As previously noted, mRNA4 is predicted to encode a 54 aa
internally deleted version of M1 [12], from the first AUG on the
transcript (Fig. 1B). Notably, the Kozak consensus [46] of AUG1 is
not optimal, lacking a G at position 4 (Figs. 1B, S1) and in the
context of segment 2, an intermediate strength initiation context
AUG1 is known to permit translation initiation at downstream
codons by a leaky ribosomal scanning mechanism [4,6,7].
Inspection of the segment 7 sequence showed another AUG
starting at position 114 in frame 2 (Fig. 1B). The predicted protein
product from this AUG would have a variant ectodomain
compared to M2, but would be identical from amino acid 10
onwards. The predicted size of the protein product would be 99
amino acids, compared to 97 for M2 (Fig. 1C).
Accordingly, we hypothesized that the U148A change induced
pseudoreversion of the V7-T9 virus via upregulation of mRNA4,
to produce a variant M2 protein (designated here ‘‘M42’’) from
AUG2 via leaky ribosomal scanning. To test this, we used reverse
genetics to first ask whether the U148A change was sufficient to
restore WT growth properties to the V7-T9 virus. Initially, a PR8
V7-T9+U148A virus was generated, along with WT, V7-T9 and a
virus with only the U148A change. Viruses were rescued by
transfecting bidirectional plasmids [47] into 293T cells, amplified
by one passage in MDCK cells and plaque titred. WT PR8 grew
to approximately 76108 PFU/ml and formed large plaques,
whereas V7-T9 had a small plaque phenotype and was attenuated
by approximately 3 log10 (Fig. 4A), consistent with previous
observations [37]. Introduction of the single U148A mutation into
the background of an otherwise WT virus did not alter virus
growth properties. However, when the change was added to the
V7-T9 background, the double mutant grew to an average of
56108 PFU/ml and produced normal-sized plaques (Fig. 4A),
confirming that the U148A mutation was necessary and sufficient
to restore WT growth properties.
To further test the M42 hypothesis, we introduced two
mutations that would be expected to block production of the
predicted novel polypeptide: either by removing its AUG codon
(U115C), or by destroying the mRNA4 SD site (G145A). Each of
these mutations was made on the background of WT segment 7, as
well as with the V7-T9, U148A or V7-T9+U148A mutations. On
a WT background, a virus with only the U115C mutation grew
normally and produced plaques indistinguishable from the WT
virus (Fig. 4A). When the U115C mutation was combined with the
U148A change, the resulting virus grew slightly less well than WT
(an average relative titre of 0.44 [n= 4]) and displayed a small
plaque phenotype. Addition of U115C to the V7-T9 mutant also
had only a minor effect on growth relative to the parent virus. In
contrast, its addition to the V7-T9+U148A background reversed
the positive effect of the U148A mutation, resulting in a virus that
grew poorly (to less than104 PFU/ml) and produced small plaques.
Similarly, the G145A mutation had no effect on virus growth as a
single mutation or when combined with the U148A change.
However, in 3 independent attempts, it was not possible to rescue
a virus with V7-T9, U148A and G145A mutations, suggestive of a
lethal phenotype.
These data indicated that pseudoreversion of the M2-null virus
required mRNA4 and also AUG2. As an additional genetic test of
the M42 hypothesis, we introduced a premature stop codon
(K70*) into the distal region of the M2 ORF that would be
common to both M2 and M42 polypeptides, but outside the M1
(or hypothetical M4) coding region. As a control K70 was also
substituted for tryptophan (K70W), a similar sequence change but
known to be compatible with M2 function [29]. It was not possible
to rescue a virus with V7-T9+U148A+K70stop, although the V7-
T9+U148A+K70W mutant grew comparably to WT and
V7+U148A viruses. Together, the genetic data are consistent
with the hypothesis that the U148A change restores growth of an
M2-deficient virus by upregulating expression of mRNA4,
allowing expression of an M2 variant from AUG2 of the
transcript.
Identification of M42, a novel M2-related polypeptide
To provide biochemical evidence for the M42 hypothesis, we
next examined segment 7 mRNA splicing by the panel of viruses in
293T cells. The V7-T9+U115C+U148A virus grew to insufficient
Figure 2. Pseudoreversion of an M2-null virus. (A). Plaque and HA titre plotted before (passage 0) and after each step of 6 serial passage
experiments as a fraction of the corresponding mean values obtained from two independent stocks of WT virus passaged in parallel. (B) Average
plaque size in MDCK cells of the indicated viruses before and after (P6) serial passage. Values are the mean + SEM of 15–92 plaques normalized to the
average WT value from each experiment. *** = p,0.001 compared to WT. (C). Segment 7 polypeptide expression. Lysates from cells infected with the
indicated viruses were analysed by SDS-PAGE and western blotting as labeled.
doi:10.1371/journal.ppat.1002998.g002
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titres to allow high multiplicity synchronous infections and the V7-
T9+G145A+U148A virus could not be rescued, so the U115C+
U148A and G145A+U148A viruses were used as proxies to analyse
the effects of the U115C and G145A mutations on mRNA
expression. Following infection, total RNA was extracted and
reverse transcriptase-primer extension reactions were performed
using a single primer capable of distinguishing segment 7 mRNAs
1–4 [17]. Separate primers specific for segment 7 vRNA and
cellular 5S rRNA were also included as controls for virus infection
and RNA recovery respectively. The levels of 5S rRNA were
equivalent between samples (Fig. 4B), demonstrating equal loading.
vRNA levels were also comparable between infected samples,
suggesting that all infections had proceeded successfully. The levels
of unspliced mRNA1 were also similar between the viruses.
However, large differences in the levels of spliced mRNAs 2 and
4 were apparent. In cells infected with the WT virus, the unspliced
transcript predominated, but abundant levels of mRNA2 (for M2)
were also present (Fig. 4B, lane 1; quantification in Fig. 4C). In
contrast, mRNAs 3 and 4 formed minor species that were only
visible on long exposure (primary data not shown, but see Fig. 4C
for quantification). As expected, mRNA2 was not detected in viruses
containing the V7-T9 mutation (Fig. 4B, lanes 5 and 6).
Importantly, and as predicted, the U148A mutation, either alone
or on a V7-T9 background, strongly upregulated production of
mRNA4 (compare lanes 1, 3 and 6). This effect was blocked when
the mRNA4 SD was destroyed with a G145A change (lane 7).
Interestingly, the changes in levels of mRNAs 2 and 4 were partly
reciprocal. Loss of the mRNA2 SD site in the V7-T9 virus was
associated with weak upregulation of mRNA4 (compare lanes 1 and
5), while improvement of the mRNA4 SD by the U148A change in
an otherwise WT background led to around a three-fold drop in
mRNA2 levels (compare lanes 1 and 3). Addition of the U115C
change to the U148A virus caused a further decrease in mRNA2
levels, but left mRNA4 levels unaltered (compare lanes 3 and 4).
Overall, these data supported the proposed mechanism of
pseudoreversion involving increased production of mRNA4.
Next, we analysed segment 7 protein expression from the
mutant viruses by western blotting for M1, and for M2 using 14C2
Figure 3. Immunofluorescent analysis of M2 expression. MDCK cells were infected with the indicated viruses at an MOI of 10, fixed at 8h p.i.,
permeabilised and stained with (A) anti M2 14C2 or (B) G74 (in green, as labeled) and (as counterstains) with anti-NP (red) and DAPI (blue) before
imaging by confocal microscopy. Extended focus projections of a series of optical sections through the depth of the cells are shown, either as merged
3-colour images or (in grey scale), the green channel alone.
doi:10.1371/journal.ppat.1002998.g003
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and G74 antisera. Lysates from the primary reverse genetics
transfections in 293T cells were used, because V7-T9+G145A or
V7-T9+G145A+U148A viruses could not be obtained. Virus
polypeptides in these lysates will therefore come from several
sources: from RNA Pol II transcription of the bidirectional
plasmid, from viral transcription in cells where active RNPs have
been reconstituted by transfection, and from spread of viable virus
through the cell culture. To control for purely plasmid-mediated
expression, lysates from a transfection where PB2 was omitted
were probed. In this sample, levels of M1 and M2 were below the
limit of detection, although they were readily visualised when all
eight plasmids were transfected (Fig. 4D, compare lanes 1 and 2).
This suggested that under these conditions, the major signal came
from viral gene expression. When mutant and WT transfections
were compared, M1 levels were broadly similar between samples,
but there was more variation in M2 levels. As expected, 14C2
reactivity was only detected from viruses with an intact mRNA2
SD (lanes 2–6) and was absent from all of the V7-T9 family of
viruses (lanes 7–12). G74 reactivity was also readily detectable in
all samples from viruses able to make mRNA2. However, in the
absence of mRNA2, it was only detectable in the V7-T9+U148A
transfected lysates (lane 10). Significantly, this was dependent on
the presence of both elevated mRNA4 levels and segment 7
AUG2, as addition of either or the G145A or U115C mutations
ablated its expression (compare lanes 10, 11 and 12).
Next, to prove the existence of the M42 polypeptide, we raised a
specific antibody against a peptide corresponding to the predicted
novel ectodomain of PR8 M42. To validate the serum, we tested it
against transfected M42 and M2, both fused to GFP. M42-GFP,
M2-GFP or GFP alone were transfected into 293T cells and the
resulting cell lysates were probed with anti-M42 and anti-M2
14C2 or G74. Samples were also probed with anti-GFP and
tubulin antisera, to confirm expression of the GFP polypeptides
and equal sample loading respectively (Fig. 5A). The anti-M42
serum detected M42-GFP with a high degree of specificity over
M2-GFP (compare lanes 1 and 2). Conversely, the 14C2 antibody
Figure 4. Genetic and biochemical evidence for pseudoreversion through upregulation of mRNA4. (A) Endpoint titres after multicycle
replication in MDCK cells of viruses with the indicated mutations to segment 7. Values are plotted are the mean + SEM of between 2 and 18
independent rescues. NR; not rescuable in 2 or more attempts. Viruses were also visually classified into normal (black bar) and small (white bar)
plaque phenotypes. (B, C) Segment 7 mRNA accumulation. Total RNA isolated from cells infected with the indicated viruses at 6 h p.i. was analysed by
RT-primer extension and urea-PAGE using primers specific for segment 7 mRNAs, vRNA or (as a loading control), cellular 5S rRNA. (C) The amounts of
mRNAs 1–4 were quantified by phosphorimager and plotted as the mean 6 SD of 3 experiments (D) Segment 7 polypeptide accumulation was
monitored by western blot analysis of lysates from 293T cells transfected with reverse genetics plasmids for the indicated viruses at 72 h post
transfection with the indicated antisera.
doi:10.1371/journal.ppat.1002998.g004
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was specific for M2-GFP, while as expected, anti-G74 detected
both M42 and M2-GFP. A preimmune bleed from the rabbits
immunized with the M42 peptide did not react with either M42-or
M2 GFP. To further probe the immunological cross-reactivity
between M2 and M42, we tested a polyclonal antiserum raised
against the entire M2 ectodomain, anti-M2e [48]. This reacted
strongly with M2-GFP and only weakly with M42-GFP, confirm-
ing the novel antigenicity of the M42 ectodomain.
Having generated a specific M42 antibody, we investigated
expression of the protein in cells infected with the panel of WT
and mutant viruses. Western blot analysis of MDCK cell lysates
using anti-tubulin sera demonstrated equivalent loading of all
samples while anti-M1 and anti-NP sera showed equal levels of
infection except in mock infected cells (Fig. 5B). WT, U115C,
G145A and G145A+U148A viruses expressed abundant quantities
of a polypeptide that reacted with 14C2 and G74 anti-M2 sera
(Fig. 5B, lanes 2–5 and 7). In contrast, the V7-T9 virus did not
produce detectable levels of any M2-related polypeptide (lane 8).
However, concomitant upregulation of mRNA4 on this back-
ground by the addition of the U148A mutation led to abundant
synthesis of an anti-M42 reactive polypeptide (lane 9), confirming
our hypothesis of a novel M2-related polypeptide. The U148A
mutation also led to synthesis of readily detectable amounts of the
M42 polypeptide when introduced into an otherwise WT
background (lane 5). M42 reactivity was however lost on this
background by mutation of AUG2 with the U115C change, or by
mutation of the mRNA4 SD using G145A (lanes 6 and 7).
Consistent with the mRNA abundance data, overall amounts of
M2 were reduced by the U148A mutation, as judged by 14C2 and
G74 staining (compare lanes 1 and 5). In addition, double staining
the same blot with the mouse 14C2 antibody in red and the rabbit
M42 antibody in green allowed the creation of a merged image
(Fig. 5B, top panel) that illustrates the similar molecular weights of
the M2 and M42 polypeptides, as well as their changing relative
abundance in response to mutations to SD sites of mRNAs 2 and 4.
Immunofluorescent staining of P6 V7-T9-infected cells suggest-
ed that the two forms of M2 localised differently within infected
cells (Fig. 3B). To test if this truly reflected a difference in
behaviour of M42 compared to M2, we infected cells with the
relevant recombinant viruses and examined M2 and M42
localisation by immunofluorescence. In WT virus infected cells,
M2 protein localized to the plasma membrane (visible as staining
of lateral membranes in single optical slices through the midline of
the cells) as well as internally, often in a perinuclear position
(Fig. 6A). Double staining for M42 however, only produced
background levels of fluorescent signal, similar to mock infected or
V7-T9 infected cells. In contrast, cells infected with the V7-
T9+U148A virus did not stain for M2 but stained strongly with
anti-M42, with the M42 signal largely present in a perinuclear
structure. Confirming that the two proteins did indeed localize
differently in infected cells, when cells infected with the U148A
virus (which expresses both proteins; Fig. 5B) were examined, the
Figure 5. Direct detection of the M42 polypeptide. (A) Validation of anti-M42 serum. Lysates from cells transfected with the indicated GFP
polypeptides were analysed by SDS-PAGE and western blotting as labeled. (B) Detection of M42 from virus-infected cells. Lysates from cells infected
with the indicated viruses at 10 h p.i. were analysed by SDS-PAGE and western blotting as labeled. The same membrane was probed with mouse anti-
M2 14C2 and rabbit anti-M42 using different colour secondary antisera; individual grey scale and colour merged images are shown.
doi:10.1371/journal.ppat.1002998.g005
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two polypeptides displayed limited colocalisation in the perinu-
clear region, but were largely in separate regions of the cell
(Fig. 6A). Double staining of cells infected with the V7-T9+U184A
virus with anti-M42 sera and a variety of markers for the cellular
exocytic pathway showed good co-localisation with GM130
(Fig. 6B and data not shown), indicating that M42 was largely
resident in the cis-Golgi apparatus. To examine intracellular
trafficking of M42 further, we created a plasmid encoding an
M42-red fluorescent protein fusion (M42-mCherry) and examined
the localization of the chimaeric protein in living cells, in
comparison to a simultaneously transfected M2-GFP fusion. Both
polypeptides co-localised in discrete cytoplasmic puncta and at the
plasma membrane, but while the intensity of GFP and mCherry
fluorescence was similar in the cytoplasmic dots, there was clearly
less of the M42-mCherry protein on the plasma membrane at
steady state (Fig. 6C). Examination of time lapse films showed that
the cytoplasmic puncta showed the expected pattern of movement
for intracellular vesicles (Videos S1, S2, S3). Overall therefore, we
conclude that like M2, M42 enters the exocytic pathway, but its
altered ectodomain affects intracellular trafficking of the protein,
resulting in a lower proportion resident at the plasma membrane.
The marked difference in intracellular localization between M2
and M42 was surprising, given that the two proteins were
apparently interchangeable with respect to virus replication in
MDCK cells (Fig. 4A). We therefore tested the effect of
modulating M42 expression on virus pathogenicity, using the
murine infection model. When either BALB/c or C57BL/6 strain
mice were infected with 100 PFU of WT PR8 virus, they lost
weight rapidly (Figs. 7A, B), showing average peak weight losses of
around 20% and substantial amounts of mortality (Fig. 7C). High
titres of virus were also recoverable from the lungs of infected
C57BL/6 mice at days 2 and 4 p.i., dropping somewhat at day 7
(Fig. 7D). In contrast, mice infected with the same titer of the M2-
null V7-T9 virus showed minimal weight loss, few signs of illness
or virus replication and no mortality. However, upregulation of
mRNA4 synthesis via U148A on the V7-T9 background
substantially increased virus replication and pathogenicity in terms
of virus titres andweight loss, although the overall mortality was
less than observed with WT virus. Conversely, increasing M42
expression by adding the U148A change on the background of a
WT virus still able to express M2 had the opposite effect,
decreasing the severity of weight loss and overall mortality,
although lung titres were not affected. Removal of the M42 AUG
codon with the U115C mutation had little effect in BALB/c mice
but led to slightly delayed weight loss and decreased mortality in
C57BL/6 mice. Overall therefore, altering the balance between
M2 and M42 expression modulated virus pathogenicity, but a
virus that only expressed M42 still caused significant disease.
Production of mRNA4 and M42 in other strains of
influenza A
The work described above demonstrated that mRNA4 encodes
a biologically significant polypeptide that can compensate for loss
of M2 expression. The question therefore arose as to whether this
might apply to other strains of IAV. The two requisites for M42
expression are production of mRNA4 and the possession of an
AUG codon in the appropriate reading frame. mRNA4 was
originally discovered in the WSN strain of virus but was not
detected in the A/Udorn/72 (Udorn) strain, a difference proposed
to result from a single nucleotide difference in the sequences
immediately surrounding the splice site: AG/GUU in WSN versus
AG/GCU in Udorn ([12]; see Fig. S1, which shows an alignment
of the viruses used or discussed in this work, in addition to the
consensus sequences of the major virus subtypes that have infected
humans this century). To test this prediction, we compared
mRNA4 synthesis in a panel of viruses with either GUA, GUU or
GCU at the 59-end of the mRNA4 intron. In agreement with the
quality of match with the consensus SD sequence, mRNA4 was
not detectable in the two viruses with a GCU sequence: human
H3N2 Udorn and H1N1 A/USSR/77 (Fig. 8A, lanes 6 and 7),
while it was most abundant in the PR8 U148A mutant (GUA; lane
2). The prediction was also partially supported when mRNA4
synthesis was examined in viruses with a GUU sequence
immediately downstream of the SD site. Intermediate quantities
Figure 6. Intracellular localization of M42. (A,B) MDCK cells were infected with the indicated viruses at an MOI of 3, fixed and permeabilised at
10 h p.i. and stained with DAPI (blue), anti-M42 and (A) anti-M2 14C2 or (B) anti-GM130. Single optical sections are shown, either as single channels or
merged overlays as labeled. (C) A549 cells were transfected with M42-mCherry and M2-GFP plasmids and imaged at 37uC without fixation 16 h later.
Single optical slices are shown. See also corresponding videos S1, S2, S3.
doi:10.1371/journal.ppat.1002998.g006
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of mRNA 4 were detected in RNA from WSN and Cambridge
PR8 virus infected cells (lanes 4 and 5; note lower overall amounts
of segment 7 mRNAs with the latter virus). Curiously however,
mRNA4 was not seen from reverse genetics PR8 (compare lanes
3–5). This was despite segment 7 of this virus only differing from
Cambridge PR8 and WSN at two nucleotide positions in the 59-
240 nucleotides, with neither change located near the mRNA4 SD
sequence (Fig. S1 and data not shown). There were also notable
differences in the amount of mRNA3 produced by the viruses,
with WSN and Udorn making abundant quantities, A/USSR/77
rather less and all three PR8 viruses making very little (Fig. 8A).
Thus mRNA4 production is predictable by examination of the SD
consensus sequence, with GUA.GUU..GCU, although other
unidentified sequence polymorphisms also play a role.
Figure 7. Pathogenicity of segment 7 mutant viruses in mice. Mice were inoculated with 100 PFU of the indicated viruses and (A, B) weight
loss measured on a daily basis. Mice were euthanised if their body weights fell below 25% of the starting value. (A) BALB/c mice were used. Data
plotted are the mean and SEM values from two independent experiments each using 5 mice/group. (B, D) C57BL/6 mice were used. Data plotted are
the mean and SEM values from a single experiment with 5 mice/group. (C) Mean and SEM nadir weights from (A, B) are plotted. Numbers over the
bars indicate the number of mice that survived/total group size. (D) Lung titres (mean and SEM) from mice sacrificed at the indicated days. Three mice
on days 2 and 7 and four mice on day 4 postinfection were used. Dashed line indicates the lower limit of detection.
doi:10.1371/journal.ppat.1002998.g007
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We therefore used this information to interrogate Genbank for
IAV segment 7 sequences likely to express M42. As of October
2011, over three-quarters of the 20,236 viruses for which useful
segment 7 sequence was available contain the M42 AUG (data not
shown). An imperfect initiation context of the M1/M2 AUG
codon (which is likely to be necessary to allow leaky ribosomal
scanning) is a very highly conserved feature of IAV (only 3 of
17256 sequences covering the M1 AUG have an optimal G at
position +4). However, the majority (,80%) of viruses are unlikely
to produce substantial amounts of mRNA4, as they possess an
unfavourable AG/GCU or otherwise non-canonical SD sequence.
In 1998, Shih and colleagues identified 8 viruses likely to make
appreciable amounts of mRNA4 [12]. Now, with an increased
number of sequences available as well as a better understanding of
the sequence elements necessary for expression of a third
biologically active protein from segment 7, we identified around
two dozen viruses likely to express M42 (Table 1), by virtue of
containing an AUG codon at positions 114–116 and an mRNA4
SD sequence of AG/GU(U/A/G). These mostly fell into three
partially overlapping groups: isolates from the early 20th Century
(human isolates from the 1930s and two classic fowl plague highly
pathogenic avian influenza (HPAI) viruses), viruses that had been
adapted to replicate in mice (the WS family, two H3N2 isolates
and PR8) and a set of HPAI isolates, mostly from the USA 1983
outbreak [49]. The latter H5N2 grouping seemed the most likely
to express large amounts of M42 because of their AG/GUA
mRNA4 SD sequence. In addition, the H5N2 outbreak spread
widely, persisted for several years and resulted in the culling of
17,000,000 poultry [50], making it an important group of non
laboratory-derived viruses, even if represented on Genbank by
relatively few sequenced isolates.
We therefore tested whether the AG/GUA mRNA4 SD
consensus of the H5N2 viruses was biologically significant. For
biosafety reasons, we used reverse genetics to create a PR8
reassortant (MPenn) with segment 7 from A/chicken/Pennsylva-
nia/10210/1986 (Penn) as well as various mutant derivatives with
alterations to the mRNA2 or 4 SD sequences or the M42 AUG
codon (Fig. S1), and then analysed their segment 7 mRNA
expression profiles. Analysis of viral RNA synthesis showed that, as
predicted by the MPenn mRNA4 SD sequence, mRNA4 was the
predominant species made from segment 7, accumulating to
markedly higher levels than either the unspliced transcript or
spliced mRNAs 2 and 3; a reversal of the ratios seen with the
‘prototype’ mRNA 4-expressing virus, WSN, where mRNA4 was
the least abundant species (Fig. 8B, compare lanes 2 and 10).
Mutations to the mRNA2 and mRNA4 SD sequences had the
expected effects. Destruction of the mRNA2 SD sequence by a
G52C change reduced mRNA2 accumulation to below detectable
levels (lane 3). Removal of the mRNA4 splice site with the G145A
change blocked detectable synthesis of mRNA4 with, as before,
the side effect of upregulating mRNA2 and mRNA3 production
(lane 5). Mutations that weakened the mRNA4 SD consensus
(A148G/U or C) dramatically reduced mRNA4 accumulation
whilst simultaneously improving synthesis of mRNAs 2 and 3
(lanes 6–9). Also as expected, these changes were specific to
segment mRNA, as the levels of segment 7 vRNA and segment 5
mRNA and cRNA were much more consistent between viruses
(Fig. 8B).
Next the impact of these changes on virus growth were assessed.
The WT MPenn reassortant virus grew well, reaching titres of
around 107 PFU/ml (Fig. 8C). Abolition of mRNA2 expression
(G52C) had no effect on virus replication; in contrast to the
attenuation seen when M2 synthesis was blocked in other virus
strains [15,36–39]. Similarly, mutations predicted to block M42
expression by destroying its AUG codon (U115C) or mRNA4
production (G145A) had no effect on virus growth. A similar lack
of effect on virus titres were seen from the mutations that
attenuated mRNA4 production: A148G, A148U and A148C.
However, double mutations targeting both M2 and M42
production were deleterious to virus growth. Viruses lacking the
M42 AUG codon or mRNA4 SD sequence could not be rescued
(in 3 attempts) in combination with the G52C mRNA 2 SD
Figure 8. Expression and functional significance of mRNA4 in other strains of IAV. (A, B) Total RNA from cells infected with the indicated
viruses at (A) an MOI of 5 and harvested at 6 h p.i. or (B) an MOI of ,1 and harvested at 9 h p.i. was analysed by RT-primer extension for cellular 5S
rRNA and virus-derived RNA species as labeled. (C) Endpoint titres after multicycle replication in MDCK cells of 7+1 reassortant PR8 viruses (PR8
MPenn) with the indicated mutations to Penn segment 7. Values are plotted are the mean + SEM of 3–14 independent rescues. NR; not rescued in 3
attempts. Viruses were also visually classified into normal (black bar) and small (open bar) plaque phenotypes.
doi:10.1371/journal.ppat.1002998.g008
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knockout (Fig. 8C). Moderate downregulation of mRNA4
production by an A148G change in the absence of mRNA 2
synthesis led to a virus that grew to high titres but with a small
plaque phenotype, while a more severe downregulation of
mRNA4 synthesis with an A148U change resulted in an additional
phenotype of very poor growth. Overall, these data indicate that
the A/chicken/Pennsylvania/10210/1986 segment 7 expresses
two functionally redundant versions of the viral ion channel, either
one of which is sufficient to support replication in cultured cells.
Thus M42 expression is not peculiar to laboratory adapted viruses
but is likely to have been a feature of a major group of HPAI
viruses that circulated for four years in North America.
Discussion
Here, we demonstrate expression of a 14th IAV polypeptide; a
variant form of the M2 protein with an alternative ectodomain,
encoded by a distinct segment 7 mRNA. This novel protein, M42,
can functionally replace M2 and support efficient replication in
tissue culture cells and pathogenicity in an animal host, despite
showing clear phenotypic differences with respect to its intracel-
lular localization. We have not directly tested M42 for proton
conductance but the PR8 MUd virus engineered to express M42
rather than M2 retained amantadine sensitivity (data not shown),
providing indirect evidence that the protein retains this function,
as expected from its identical transmembrane domain sequence to
M2. The ability of M42 to support efficient virus replication
despite its inefficient transport to the plasma membrane is
interesting in light of current theories regarding the role of M2
in membrane scission [32].
Like the three other IAV ‘‘accessory’’ genes that were
discovered long after the virus genome was sequenced (PB1-F2,
PB1-N40 and PA-X; [4–6]), M42 is clearly non-essential for virus
replication, as long as sufficient M2 is expressed. Unlike the
additional proteins expressed from the P protein genes, M42
expression is likely to be restricted to a minority of IAV strains
under normal conditions, as a result of the suboptimal SD
sequence of mRNA4. Examination of the consensus sequences for
the major subtypes of IAV that have infected humans in the last
century showed that (in consensus, with occasional exceptions) all
possess(ed) a weak mRNA4 SD sequence (GCU at the intron
boundary) of the type found in Udorn (Fig. S1). However, all these
viruses except the current 2009 swine-origin pandemic virus also
contain the M42 AUG codon as well as an imperfect Kozak
Table 1. Viruses known or likely to express M42.
Accession SD Virus name Year Notes
L37797 AG/GUU A/chicken/Weybridge (H7N7) 1927? (a)
L25814 AG/GUU A/NWS/1933 (H1N1) 1933 (b)
M19374 AG/GUU A/WSN/1933 (H1N1) 1933 (b)
EF467824 AG/GUU A/Puerto Rico/8/34 (H1N1) 1934 (c)
M55474 AG/GUU A/chicken/Rostock/1934 (H7N1) 1934 (a)
CY019956 AG/GUU A/Alaska/1935 (H1N1) 1935
X08090 AG/GUU A/Port Chalmers/1/1973-mouse adapted (H3N2) 1973 (b)
CY114430 AG/GUU A/Bangkok/1/1979 (H3N2) 1979
CY065977 AG/GUU A/Philippines/2-MA/1982 (H3N2) 1982 (b)
CY043729 AG/GUU A/Siena/3/1991 (H3N2) 1991
FJ784879 AG/GUU A/chicken/Hunan/1793/2007 (H5N1) 2007 (a)
GU052788 AG/GUA A/chicken/Pennsylvania/21525/1983 (H5N2) 1983 (a)
FJ610128 AG/GUA A/chicken/MA/11801/1986 (H5N2) 1986 (a)
CY015074 AG/GUA A/chicken/Pennsylvania/1/1983 (H5N2) 1983 (a)
GU052756 AG/GUA A/turkey/Virginia/6962/1983 (H5N2) 1983 (a)
GU052780 AG/GUA A/chicken/Florida/27716-2/1986 (H5N2) 1986 (a)
FJ610122 AG/GUA A/chicken/NJ/12508/1986 (H5N2) 1986 (a)
EU980474 AG/GUA A/chicken/OH/22911-10/1986 (H5N2) 1986 (a)
GU052748 AG/GUA A/chicken/Pennsylvania/10210/1986 (H5N2) 1986 (a)
FJ357092 AG/GUA A/guinea fowl/OH/22911-20/1986 (H5N2) 1986 (a)
EU743053 AG/GUA A/chicken/NY/12004-3/1987 (H5N2) 1987 (a)
EU743234 AG/GUA A/goose/OH/22911-2/1986 (H5N2) 1986 (a)
GU052772 AG/GUG A/chicken/Pennsylvania/1370/1983 (H5N2) 1983 (a)
EU743059 AG/GUG A/chicken/FL/22780-2/1988 (H5N2) 1988 (a)
GU052740 AG/GUG A/chicken/Pennsylvania/4104/1983 (H5N2) 1983 (a)
20,245 sequences available on the NCBI database were analysed on Oct 10th, 2011, with a repeat search for new sequences of the form AG/GU on July 2nd 2012. The
table excludes duplicate sequences, PR8 vaccine reassortants and over 50 cases where supposedly unique sequences showed phylogenetically implausible levels of
similarity to PR8 or WSN, suggestive of mistakes in data curation or laboratory contamination of virus stocks.
aHighly pathogenic avian influenza virus, by the molecular definition of possessing a polybasic HA cleavage site.
bChange from AG/GCU SD sequence seen after virus adapted to replicate in mice.
cMouse adapted virus but original virus sequence not available.
doi:10.1371/journal.ppat.1002998.t001
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consensus around the M1/M2 AUG codon (Fig. S1), suggesting
the potential for M42 expression should mRNA4 expression be
present. This perhaps argues that there are environments in which
it is advantageous for IAV to shift the balance of segment 7
splicing away from the normal mRNA2/M2 route to increased
mRNA4/M42. In this respect it is noteworthy that increased
mRNA4 synthesis has been selected for on at least three, probably
four, occasions on different virus backgrounds during adaptation
to growth in mice (Table 1). Also, given the Golgi-biased
localisation of M42, it is tempting to draw a link between the
requirement for pH-modulation of the Golgi during intracellular
transport of HA molecules with polybasic cleavage sites [25,51]
and the overrerpresentation of HPAI viruses in the list of those
likely to express M42. We also speculate that the altered
antigenicity of the M42 ectodomain might provide the virus with
a route to escape selection pressure imposed by a vaccine directed
against the M2e sequence, given that in many viruses, a single
nucleotide change would be predicted to alter the balance of
splicing towards M42.
The viruses in which we can be reasonably confident of M42
expression represent a very small minority (,0.2%) of the
available sequences. However, there are two further considerations
that may render M42 expression more widespread in IAV than
our conservative prediction in Table 1. Firstly, we do not yet fully
understand what controls segment 7 splicing. A sizeable number of
viruses (around 15%; mostly from avian hosts) have an mRNA4
SD sequence of AG/GCA. An A at position+3 clearly promotes
more efficient use of the splice site when position +2 is U but it
remains to be determined if it is sufficient to override a C at +2.
Furthermore, the differences in relative splicing seen between PR8
and WSN viruses make it clear that sequence elements outside of
the core consensus splice sites affect their use; these sequences are
identical in the two viruses but their splicing patterns are very
different. Analysis of a 7+1 PR8:WSN reassortant indicates that
the difference is intrinsic to segment 7 (HW, PD, unpublished
data) but we have not yet identified the sequence determinants.
Secondly, there are many precedents for cell-type dependence of
alternative splicing in cellular mRNAs [52] so it may be that in
some host species and/or cell types, M42 expression is present in a
wider array of IAV strains. Further experiments are required to
test these hypotheses.
Materials and Methods
Ethics statement
Animal experiments were carried out in strict accordance with
the recommendations in the Guide for the Care and Use of
Laboratory Animals under the auspices of an NIH Animal Care
and Use Committee-approved animal study protocol. The
protocol was approved by the NIAID Animal Care and Use
Committee (Permit Number LID-6E). All efforts were made to
minimize suffering.
Cells, viruses, plasmids and antisera
Madin-Darby Canine Kidney, 293T human embryonic kidney
and A549 human lung adenocarcinoma cells were cultured
according to standard procedures [53]. A reverse genetics clone
of influenza PR8 and its M2-null derivative, V7-T9 have been
previously described [37,47]. A clone of A/chicken/Pennsylvania/
10210/1986 (GU052748) with the UTRs derived from A/
chicken/Pennsylvania/1/1983 (CY015074; where a complete
segment sequence was available) was synthesized by Genscript
and cloned into pDUAL reverse genetics vector [47]. Further
mutants were made using the 8 bidirectional promoter plasmid
system described in [47], following oligonucleotide-directed
mutagenesis to introduce the desired changes, as indicated in
Fig. S1. Primer sequences are available upon request. Non-
recombinant Cambridge lineage PR8 virus, A/USSR/77 and A/
WSN/33 viruses were obtained from the University of Cambridge
Division of Virology’s collection of viruses. A/Udorn/72 was a gift
from Professor Compans [54]. M2 and M42-GFP tagged
expression constructs were produced by cloning the coding
sequences of the respective proteins into the KpnI/AgeI sites of
pEGFP-N1 (Clontech). An M42-mCherry fusion was made by
substituting the EGFP open reading frame with mCherry.
Purchased monoclonal antisera were against ß-tubulin (clone
YL1/2: AbD-Serotec), GM130 (Clone 610822; BD Transduction
Laboratory), GFP (clone JL8, Clontech) and anti-influenza M2
(Clone 14C2, Abcam). Further anti-M2 reagents of a goat
polyclonal (G74) raised against the whole protein and a mouse
polyclonal raised against the M2 ectodomain (M2e) were the
generous gifts of Drs. Alan Hay and Xavier Saelens, respectively.
Rabbit polyclonal anti-M1 (A2917) and anti-NP (A2915) have
been previously described [55,56]. Affinity purified anti-M42
specific serum was purchased from Genscript. Rabbits were
immunized with a peptide corresponding to the N-terminal 16
amino acids of the protein, MSLQGRTPILRPIRNE (where
unique sequences compared to M2 are underlined).
Virus rescue, growth and titration
Recombinant viruses were rescued by 8 plasmid transfection
into 293T cells followed by amplification in MDCK cells as
previously described [37]. In some cases, stocks were further
amplified by growth in day 10–12 embryonated eggs, also as
described [37]. Tissue culture cells were infected by allowing virus
to adsorb for 30–60 min in serum free medium. For synchronous
analyses of viral RNA and protein synthesis, infections were
carried out at an MOI of 3–10. For analyses of virus growth,
infections were initiated at low multiplicity and cells overlaid with
serum free medium supplemented with 1 mg/ml trypsin
(Worthington Biochemicals) and 0.14% bovine serum albumin.
Serial passages were performed by infecting 36106 MDCK cells at
an MOI of 0.01. At 48 h p.i., the medium was clarified and 10 ml
(of 5 ml) used to infect fresh MDCK cells. This procedure was
repeated a further five times.
Plaque assays were carried out in MDCK cells using an Avicel
overlay followed by staining with toluidine blue [37,57]. Plaque
areas were measured from scanned images using an oval selection
marquee in the program Image J [58] and calibrated with respect
to the area of a 6-well dish. HA assays were performed using 1%
chicken red blood cells in 96 well plates according to standard
procedures [37].
Mouse infection
Infection of C57BL/6J or BALB/c mice (strains 664 and 1026,
JAX Mice and Services) was carried out under animal BSL3
conditions at the National Institutes of Health. Groups of five 9–10
week old female mice were infected intranasally with 100 PFU of
virus in 50 ml DMEM under oxygenated isoflurane anesthesia.
Mice were individually identified and weighed daily; mice losing
25% or more of their initial body weight were euthanised. Three
mice on days 2 and 7 and four mice on day 4 postinfection were
euthanised and lungs collected for weight-normalized homogeni-
zation and MDCK plaque titration.
RNA and protein analyses
Total cellular RNA was extracted using Trizol (Sigma) and
individual RNA species detected using radiolabelled reverse
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transcriptase primer extension followed by urea-PAGE and
autoradiography as previously described [17,59]. The primer
GAAGGCCCTCCTTTCAGTCC, which targeted nucleotides
885–904 in mRNA sense, was used to detect segment 7 mRNA.
Quantitation was performed using Fujifilm imaging plates and a
Fujifilm FLA-5000 fluorescent image analyser. Data was analysed
using AIDA software (Raytest). SDS-PAGE followed by western
blotting was performed according to standard procedures. Blots
were developed using infrared fluorescent secondary antibodies
and imaged using a LiCor Biosciences Odyssey platform. Cells
were stained for immunofluorescence after formaldehyde fixation
using primary followed by Alexa-fluor conjugated secondary
antibodies (Invitrogen) as previously described [60] and imaged
on Zeiss LSM510, Leica SPE or TCS-NT confocal microscopes.
Live cell imaging was performed in a temperature-controlled hood
and CO2-independent medium as previously described [53].
Supporting Information
Figure S1 Alignment of IAV segment 7 splice site
sequences from strains either used or discussed in this
study. Individual cDNA sequences are shown for PR8 (Reverse
genetics (RG) clone EF467824), WSN (CY034133), Udorn
(324335) and Penn (GU052748) viruses. Partial consensus
sequences for the regions of interest from indicated strains of
human-infecting viruses (H1N1, H2N2, H3N2 and pdm2009
viruses as well as human-derived H5N1 post 1997) were generated
by multiple alignment of publicly available sequences on GenBank
in August 2011. AUG codons are highlighted in bold and
underlined. Positions mutated in PR8 or Penn segment 7 in this
study are highlighted in red and labeled with arrows. Consensus
sequences for cellular splice donor (SD), splice acceptor (SA) and
Kozak sequences surrounding AUGs 1 and 2 are shown above the
sequences in bold (M: A or C; R: A or G; Y: C or T). Sequences
shown to be important for binding the cellular splicing factor
ASF/SF2 [62] are also shown. Matches to the cellular consensus
are shaded in green.
(TIF)
Video S1 Live cell imaging of M2 and M42. A549 cells
were transfected with plasmids encoding M42-mCh and M2-GFP,
and imaged 16 h p.i. Cells were imaged at 37uC in CO2-
independent medium on a Leica SPE confocal microscope. The
video shows a merged image of red and green channels.
(MOV)
Video S2 Live cell imaging of M2. As above (Video S1), but
showing the green (M2-GFP) channel only.
(MOV)
Video S3 Live cell imaging of M42. As above (Video S1), but
showing the red (M42-mCh) channel only.
(MOV)
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